Wegovy Weight Loss Drug Faces Compounding Ban and Market Shifts Amid Breakthrough Obesity Treatment Developments
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Wegovy Weight Loss Drug Faces Compounding Ban and Market Shifts Amid Breakthrough Obesity Treatment Developments
-
Narrado por:
-
De:
Acerca de esta escucha
Explore the complex world of Novo Nordisk's groundbreaking weight loss drug Wegovy with veteran global health journalist Alexandra Reeves. This eye-opening episode delves into the recent federal ban on compounded semaglutide, Novo Nordisk's response with discounted patient offers, and the intensifying competition from Eli Lilly's Zepbound. Learn about the promising oral semaglutide pill awaiting FDA approval, leadership changes in Europe, and the ongoing challenges of accessibility and equity in obesity treatment. Discover how this revolutionary medication achieving 15% average weight loss is reshaping healthcare systems worldwide while navigating regulatory hurdles, scientific advancement, and patient advocacy concerns. Perfect for healthcare professionals, patients considering weight loss treatments, or anyone interested in the intersection of pharmaceutical innovation and global health policy.
adbl_web_global_use_to_activate_webcro805_stickypopup
Todavía no hay opiniones